Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Chardan Capital, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Palvella Therapeutics Inc., all published on August 12, 2026.
Last mentioned: Aug 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Chardan Capital, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Palvella Therapeutics Inc., all published on August 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 11 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Palvella Therapeutics Inc.. Shared-story counts are live from our verified record — not editorial picks.
Palvella Therapeutics stock sank 12.4% Monday with no news, highlighting biotech liquidity risk. Analyst consensus target of $199.53 implies 45% upside, but earnings miss and two sell ratings complicate the picture for biotech investors.
Source: dailypolitical.com · tickerreport.com
Palvella Therapeutics Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
